Cytidine deaminase deficiency in tumor cells is associated with sensitivity to a naphthol derivative and a decrease in oncometabolite levels

Identifying new molecular targets for novel anticancer treatments is a major challenge in clinical cancer research. We have shown that cytidine deaminase (CDA) expression is downregulated in about 60% of cancer cells and tissues. In this study, we aimed to develop a new anticancer treatment specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Mameri, Hamza, Buhagiar-Labarchède, Géraldine, Fontaine, Gaëlle, Corcelle, Céline, Barette, Caroline, Onclercq-Delic, Rosine, Beauvineau, Claire, Mahuteau-Betzer, Florence, Amor-Guéret, Mounira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352748/
https://www.ncbi.nlm.nih.gov/pubmed/35925417
http://dx.doi.org/10.1007/s00018-022-04487-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352748/
https://www.ncbi.nlm.nih.gov/pubmed/35925417
http://dx.doi.org/10.1007/s00018-022-04487-9

Ejemplares similares